Chronic kidney disease (NICE TA775)
1.1 Dapagliflozin is recommended as an option for treating chronic kidney disease (CKD) in adults. It is recommended only if:
it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and
people have an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 to 75 ml/min/1.73 m2 at the start of treatment and:
have type 2 diabetes or
have a urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more.
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist